PPID _ CyP_40
- Known as:
- PPID _ CyP_40
- Catalog number:
- Y213700
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- PPID _ CyP_40
Related genes to: PPID _ CyP_40
- Gene:
- PPID NIH gene
- Name:
- peptidylprolyl isomerase D
- Previous symbol:
- -
- Synonyms:
- CYP-40
- Chromosome:
- 4q32.1
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-23
- Date modifiied:
- 2016-10-05
Related products to: PPID _ CyP_40
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial,24-OHase,Cyp24,Cyp-24,Cyp24a1,Cytochrome P450 24A1,Cytochrome P450-CC24,Mouse,Mus musculus,Vitamin D(3) 24-hydroxylase40 kDa peptidyl-prolyl cis-trans isomerase,Bos taurus,Bovine,Cyclophilin-40,Cyclophilin-related protein,CYP-40,CYPD,Estrogen receptor-binding cyclophilin,Peptidyl-prolyl cis-trans isomerase D,PPIase D40 kDa peptidyl-prolyl cis-trans isomerase,Cyclophilin-40,Cyclophilin-related protein,CYP40,CYP-40,CYPD,Homo sapiens,Human,Peptidyl-prolyl cis-trans isomerase D,PPIase D,PPID,Rotamase D40 kDa peptidyl-prolyl cis-trans isomerase,Cyclophilin-40,CYP-40,Mouse,Mus musculus,Peptidyl-prolyl cis-trans isomerase D,PPIase D,Ppid,Rotamase D40 kDa peptidyl-prolyl cis-trans isomerase,Cyclophilin-40,CYP-40,Peptidyl-prolyl cis-trans isomerase D,PPIase D,Ppid,Rat,Rattus norvegicus,Rotamase DAnti- PPID CyP-40 Antibodyanti-Cyclophilin D，PPIDanti-PPID (4C7)Anti-PPID Antibodyanti-PPID(4C7)Anti-recombinant CYP-33E1 Monoclonal AntibodyAntibodies: PPID _ CyP-40 HOST: Goat Clonality: pAbAntigens Cyclophilin D(PPID), 1- 370aa, Human, His-tagged, Recombinant, E.coliBovine Peptidyl-prolyl cis-trans isomerase D(PPID) ELISA kitBovine Peptidyl-prolyl cis-trans isomerase D(PPID) ELISA kit SpeciesBovine Related articles to: PPID _ CyP_40
- Kawasaki disease (KD) is a systemic vasculitis of childhood driven by aberrant immune activation. Natural killer (NK) cell dysregulation plays a critical role, but its upstream molecular mechanisms remain unclear. Isonicotinylation (Kinic), a novel lysine acylation acting as a metabolic sensor, represents an unexplored regulatory layer in KD. - Source: PubMed
Publication date: 2026/07/22
Yang YanliHu Pengjuan - Protein translocation across the bacterial SecYEG channel involves mechanical constraints arising from ATP-driven SecA activity, geometric confinement within the translocon, and folding of the emerging polypeptide on the periplasmic side. Periplasmic chaperones assist substrate maturation during this process, but how they influence protein folding under force remains poorly understood. Using protein L as a model two-state substrate, we applied physiologically relevant force pulses using custom-built single-molecule magnetic tweezers to examine how bacterial periplasmic chaperones modulate folding under tension. To isolate the direct effects of individual chaperones, these experiments were performed in the absence of SecA and the SecYEG translocon. We show that the periplasmic chaperones PpiD and DsbC increase folding probability and accelerate refolding under force, while having minimal effect on unfolding kinetics. In contrast, Spy and Skp reduce folding probability and suppress refolding, consistent with holdase-like behaviour. These observations show that distinct classes of periplasmic chaperones differentially modulate folding probability and refolding kinetics under mechanical force. Increased folding probability correspondingly enhances the expected mechanical work output of substrate folding under force. Together, our findings establish a quantitative framework for investigating how bacterial periplasmic chaperones modulate protein folding under controlled mechanical conditions. - Source: PubMed
Publication date: 2026/08/01
Chaudhuri DeepBhatt MadhuHaldar Shubhasis - Breast cancer (BC) is the most common malignancy among women worldwide. Although observational studies have linked carnitine-related metabolites (CRMs) to BC, causal inference has been limited by confounding and reverse causality. This study used Mendelian randomization (MR) analysis to investigate the potential causal link between CRMs and BC. - Source: PubMed
Publication date: 2026/04/03
Ran FeifengQue LilinLuo LanGan MeiWang RenshengLiang Leifeng - Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease characterized by persistent inflammation, aberrant extracellular matrix remodeling, and impaired tissue repair. Current antifibrotic drugs can slow disease progression but cannot reverse established fibrosis, highlighting the need to identify novel mechanism-based therapeutic targets. - Source: PubMed
Publication date: 2026/06/05
Chen XingxuanChen ShibinZhao ShuaiLi YupengChang JingkunShi SiXu DandanLi LijuanChen Hong - Ertugliflozin is a sodium-glucose co-transporter-2 inhibitor that has demonstrated promise as a treatment for hyperinsulinaemia in horses. Despite the frequent use of ertugliflozin in equine clinical practice, the pharmacokinetics of this drug in horses has not been established. The aim of the present study was to determine the pharmacokinetics of one supratherapeutic dose (0.25 mg/kg) of ertugliflozin in eight horses. Horses were defined as being healthy by physical examination, haematological, blood biochemical and oral sugar test (OST) results. Plasma concentrations of ertugliflozin were quantified using high-performance liquid chromatography-tandem mass spectrometry 0, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 14, 18, 24, 30, 36, 48, 60, 72, 96, and 120 h after drug administration enterally. Non-compartmental analysis led to determination of key pharmacokinetic variables, including mean ± SD time to maximum concentration (T of 0.91 ± 0.13 h, maximum measured concentration (C of 267.52 ± 25.37 ng/mL, terminal elimination half-life (T) of 17.65 ± 3.15 h and apparent oral clearance (CL/F) of 106.95 ± 27.53 mL/h/kg. No clinical signs of adverse effects or blood biochemical abnormalities occurred after drug administration. The results of this study suggest that a single supratherapeutic dose of ertugliflozin in healthy horses is safe. The pharmacokinetics of enterally administered ertugliflozin in horses are similar to pharmacokinetics of the drug in humans and the long T makes ertugliflozin suitable for once daily dosing in horses. It is proposed that a starting dose for ertugliflozin in horses be in the range 0.05-0.1 mg/kg. Further pharmacokinetic studies are required to optimise the dose regimen for treating horses with hyperinsulinaemia. - Source: PubMed
Publication date: 2026/05/01
Kirkwood Naomi CHughes Kristopher JLovett Amy LDoran Gregory SRendle David IEdwards Scott H